Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital

A systematic review of blood eosinophils and continued treatment with inhaled corticosteroids in patients with COPD

Publikation: Bidrag til tidsskriftReviewForskningpeer review


  1. Sex differences between women and men with COPD: A new analysis of the 3CIA study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prognosis of COPD depends on severity of exacerbation history: A population-based analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Interstitial lung abnormalities are associated with increased mortality in smokers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Reducing socioeconomic inequalities in COPD care in the hospital outpatient setting - A nationwide initiative

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Characteristics of COPD Patients Prescribed ICS Managed in General Practice vs. Secondary Care

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Inter-Day Test-Retest Reproducibility of the CAT, CCQ, HADS and EQ-5D-3L in Patients with Severe and Very Severe COPD

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Dagmar Abelone Dalin
  • Anders Løkke
  • Pernille Kristiansen
  • Charlotte Jensen
  • Kirsten Birkefoss
  • Hanne Rolighed Christensen
  • Nina Skavlan Godtfredsen
  • Ole Hilberg
  • Jeanett Friis Rohde
  • Anja Ussing
  • Charlotte Vermehren
  • Mina Nicole Händel
Vis graf over relationer

Inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) has been debated for 20 years. In our systematic literature review and meta-analysis, we addressed the following: Should patients with COPD and a blood eosinophil count (EOS) of, respectively, a) < 150 cells/μl, b) 150-300 cells/μl, and c) > 300 cells/μl continue treatment with ICS? Protocol registered in PROSPERO (CRD42020178110) and funded by the Danish Health Authority. We searched Medline, Embase, CINAHL and Cochrane Central on 22nd July 2020 for randomized controlled trials (RCT) of ICS treatment in patients with COPD (≥40 years, no current asthma), which analyzed outcomes by EOS count and where >50% of patients used ICS prior. We used the GRADE method. Meta-analyzes for the outcomes were divided into EOS subgroups and analyzed for differences. We identified 11 RCTs with a total of 29,654 patients. A significant difference (p < 0.00001) between the three subgroups' reduction of risk of moderate to severe exacerbation was found. Rate ratios for EOS counts: <150 cells/μL was 0.88 (95%CI: 0.83, 0.94); 150-300 cells/μL was 0.80 (95%CI: 0.69, 0.94); >300 cells/μL was 0.57 (95%CI: 0.49, 0.66). Overall, the certainty of the effect estimates was low to very low due to risk of bias, unexplained heterogeneity, few RCTs, and wide confidence intervals. A clear correlation was demonstrated between effect of continued ICS treatment (number of exacerbations, lung function, and quality of life) and increasing EOS count. Our meta-analyses suggested that treatment with ICS seemed beneficial for everyone except patients with EOS count below 150 cells/μl.

TidsskriftRespiratory medicine
Sider (fra-til)106880
StatusUdgivet - jul. 2022

Bibliografisk note

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

ID: 78224597